


Article

Design, Catalyst-Free Synthesis of New Novel α -Trifluoromethylated Tertiary Alcohols Bearing Coumarins as Potential Antifungal Agents

Shengfei Jiang ¹, Guoyu Yang ¹, Lijun Shi ¹, Liangxin Fan ¹ , Zhenliang Pan ¹, Caixia Wang ¹, Xiaodan Chang ¹, Bingyi Zhou ¹, Meng Xu ², Lulu Wu ^{1,*} and Cuilian Xu ^{1,*}

¹ College of Sciences, Henan Agricultural University, Zhengzhou 450002, China

² Department of Information, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China

* Correspondence: wululu@henau.edu.com (L.W.); xucuilian666@henau.edu.com (C.X.)

Abstract: A new method for the synthesis of α -trifluoromethylated tertiary alcohols bearing coumarins is described. The reaction of 3-(trifluoroacetyl)coumarin and pyrrole provided the target compounds with high yields under catalyst-free, mild conditions. The crystal structure of compound **3fa** was investigated by X-ray diffraction analysis. The biological activities, such as in vitro antifungal activity of the α -trifluoromethylated tertiary alcohols against *Fusarium graminearum*, *Fusarium oxysporum*, *Fusarium moniliforme*, *Rhizoctonia solani* Kuhn, and *Phytophthora parasitica* var *nicotianae*, were investigated. The bioassay results indicated that compounds **3ad**, **3gd**, and **3hd** showed broad-spectrum antifungal activity in vitro. Compound **3cd** exhibited excellent fungicidal activity against *Rhizoctonia solani* Kuhn, with an EC₅₀ value of 10.9 μ g/mL, which was comparable to that of commercial fungicidal triadimefon (EC₅₀ = 6.1 μ g/mL). Furthermore, molecular docking study suggested that **3cd** had high binding affinities with 1W9U, like argifin.

Keywords: α -trifluoromethylated tertiary alcohol; coumarin; catalyst-free; antifungal activity



Citation: Jiang, S.; Yang, G.; Shi, L.; Fan, L.; Pan, Z.; Wang, C.; Chang, X.; Zhou, B.; Xu, M.; Wu, L.; et al. Design, Catalyst-Free Synthesis of New Novel α -Trifluoromethylated Tertiary Alcohols Bearing Coumarins as Potential Antifungal Agents. *Molecules* **2023**, *28*, 260. <https://doi.org/10.3390/molecules28010260>

Academic Editor: Pei Li

Received: 1 December 2022

Revised: 23 December 2022

Accepted: 26 December 2022

Published: 28 December 2022

1. Introduction

Trifluoromethylated compounds, due to their unique properties, are of utmost interest for a wide cross-section of chemists [1–5]. Among them, α -trifluoromethylated tertiary alcohol motifs are found in various pharmaceuticals (Figure 1) [6–13]. For example, α -trifluoromethylated tertiary alcohol **A** and efavirenz are HIV reverse transcriptase inhibitors, B1653048 and MK-0633, respectively, are glucocorticoid agonist and 5-lipoxygenase inhibitor.




Figure 1. Examples of pharmaceuticals containing α -trifluoromethylated tertiary alcohol motifs.

Therefore, several examples of the synthesis of trifluoromethylated tertiary alcohols have been described [14–18]. From all the methodologies described, the Friedel–Crafts alkylation reaction with trifluoromethyl ketones is one of the most straightforward approaches for the synthesis of this kind of tertiary alcohols [19–22]. Among these reported examples, most of them use trifluoromethyl ketones as acceptors in addition reactions (Figure 2a) [23–25]. Interestingly, we noted that when α,β -unsaturated trifluoromethyl ketones were used as acceptors, the adducts are 1,4-addition rather than 1,2-addition (Figure 2b) [26–29]. As a part



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

of our continuing work in the functionalization of coumarins [30–34], coumarin-bearing α,β -unsaturated trifluoromethyl ketones were selected as electrophiles instead of trifluoromethyl ketones to obtain trifluoromethylated tertiary alcohols (Figure 2c).





Figure 2. Friedel–Crafts alkylation of indole or pyrrole and trifluoromethylketone or α,β -unsaturated trifluoromethyl ketone.

Coumarin is an important heterocyclic skeleton frequently found in numerous natural products, pharmaceutical molecules, fluorescent probes, and materials [35–42]. The combination of some privileged structures, a benzopyrone ring, a trifluoromethyl moiety, and a pyrrole ring for the synthesis of quaternary carbon organic molecules could be of significant importance, especially for new drugs and materials.

In this paper, we describe the first synthetic method for the preparation of α -trifluoromethylated tertiary alcohols bearing coumarins. Our approach is based on the two-component reaction of 3-(trifluoroacetyl)coumarin and pyrrole, and this method required neither catalyst/additive nor special conditions. In addition, the *in vitro* antifungal activity of the title compounds was also studied.

2. Results and Discussion

We readily prepared 3-(trifluoroacetyl)coumarin **1a** in two steps and directly used it as an electrophile for the Friedel–Crafts alkylation of 2-methylpyrrole **2a**. During the process of exploring reaction conditions, we were initially pleased to find that the reaction proceeded smoothly in CH_2Cl_2 at room temperature to provide the desired product **3aa** with 46% yield in the presence of 5 mol % of AlCl_3 (Table 1, entry 1). The success indicated that the reaction could be promoted by Lewis acid. Subsequently, a series of Lewis acids were screened, and the reactions could proceed (Table 1, entries 2–6). However, unfortunately, only low yields of tertiary alcohol product were formed. To our surprise, 97% yield was observed by performing the reaction in the absence of catalyst (Table 1, entry 7). Finally, the reaction media were screened. Solvent evaluation indicated that the solvents have a remarkable influence on the yields (Table 1, entries 7–15). The yield sharply decreased when chloroform, ethyl acetate, acetonitrile, toluene, and tetrahydrofuran were used as the solvents (Table 1, entries 8–12). Methylene chloride was the best solvent, giving the highest yield of 97%. Unfortunately, the yield sharply decreased when reducing the reaction temperature to 0 °C (Table 1, entry 16).

Table 1. Optimization of the reaction 3-(trifluoroacetyl)coumarin **1a** and 2-methylpyrrole **2a** ^a.


Entry	Catalyst	Solvent	Temp. (°C)	Yield (%) ^b
1	AlCl ₃ (5%)	CH ₂ Cl ₂	25	46
2	FeCl ₃ (5%)	CH ₂ Cl ₂	25	39
3	CuCl ₂ (5%)	CH ₂ Cl ₂	25	41
4	CH ₃ COOAg (5%)	CH ₂ Cl ₂	25	40
5	Sc(OTf) ₃ (5%)	CH ₂ Cl ₂	25	20
6	Cu(OTf) ₂ (5%)	CH ₂ Cl ₂	25	46
7	—	CH ₂ Cl ₂	25	97
8	—	CHCl ₃	25	48
9	—	EtOAc	25	20
10	—	CH ₃ CN	25	35
11	—	toluene	25	21
12	—	THF	25	36
13	—	dioxane	25	55
14	—	ClCH ₂ CH ₂ Cl	25	78
15	—	BrCH ₂ CH ₂ Br	25	68
16	—	CH ₂ Cl ₂	0	36

^a Reactions were performed with **1a** (1.0 mmol) and **2a** (1.0 mmol), with catalyst (1%) or without catalyst in the solvent (1.5 mL). ^b Isolated yield.

Having established the preferred reaction conditions, we next examined the substrate scope of the Friedel–Crafts reaction (Table 2). A range of 3-(trifluoroacetyl)coumarins with different substituents at the 6-, 7-, or 8- positions proceeded smoothly to afford the corresponding α -trifluoromethyl tertiary alcohols **3aa–ia** with excellent yields. Subsequently, pyrroles **2b–f** with different groups were also tested for this synthesis. They proceeded well, furnishing the desired products **3ab–af** with moderate to excellent yields. The position and electronic property of substituents had a remarkable influence on the yields. The pyrrole ring with electron-donating substituents at the 2-, 3-, or 4- positions proceeded smoothly to afford the corresponding α -trifluoromethyl tertiary alcohols with excellent yields, while the presence of electron-donating substituents in the 2- and 5- positions had a detrimental effect on the yield, due to the activity of the 2-position pyrrole higher than the 3-position. It was gratifying that excellent yields could be achieved by adding Sc(OTf)₃ and increasing the reaction temperature. Unfortunately, the pyrrole ring with an electron-deficient group was an infeasible substrate, presumably because electron withdrawal affected the activity of the pyrrole. Notably, when the pyrrole and N-methylpyrrole were employed, a comparable yield was obtained.


To test the feasibility of potential large-scale application of the process, the reaction of 3-(trifluoroacetyl)coumarin **1a** with 2-methylpyrrole **2a** was carried out at the 10 mmol scale under the standard conditions (Scheme 1). The reaction furnished a 95% yield of the product **3aa**, which is quite comparable to the yield obtained in the small scale reaction (97% yield).

To determine the structures of the products, a single crystal of compound **3fa** was obtained (Figure 3). The structures of other products can therefore be determined by analogy.

The in vitro antifungal activity of target compounds **3aa–3hd** against six representative phytopathogens is summarized in Table 3. Triadimefon was used as a positive control at a concentration of 10 μ g/mL. In general, the title compounds exhibited a certain degree of fungicidal activity at a concentration of 500 μ g/mL. Among them, compounds **3ad**, **3bd**, and **3cd** showed over 90% inhibition against *F. graminearum* (from corn). Compounds **3ad**, **3bd**, **3gd**, and **3hd** showed over 80% inhibition against *F. oxysporum*. Compounds **3ad** and


3bd showed over 80% inhibition against *F. graminearum* (from wheat). In particular, **3ad**, **3gd**, and **3hd** exhibited excellent activity (>98%) against *R. solani* Kuhn. Compounds **3ac**, **3ad**, **3bd**, **3gd**, and **3hd** exhibited higher antifungal activity (> 80%) against *P. parasitica* var *nicotianae*. Furthermore, it was also worth noting that **3ad**, **3gd**, and **3hd** exhibited broad-spectrum antifungal activity and could be considered as new fungicidal leads for further optimization.

Table 2. Reaction scope of the Friedel–Crafts reaction of 3-(trifluoroacetyl)coumarin **1** with pyrroles **2** ^a.



Entry	R ¹	R ²	R ³	Product	Yield ^b
1	H	2-Me	H	3aa	97
2	6-Me	2-Me	H	3ba	85
3	6-Cl	2-Me	H	3ca	91
4	6-Br	2-Me	H	3da	84
5	7-OMe	2-Me	H	3ea	97
6	8-OMe	2-Me	H	3fa	85
7	6,8-(Cl) ₂	2-Me	H	3ga	95
8	6,8-(Br) ₂	2-Me	H	3ha	90
9	naphthyl	2-Me	H	3ia	89
10	H	2,4-(Me) ₂	H	3ab	93
11	8-OMe	2,4-(Me) ₂	H	3fb	84
12 ^c	H	2,5-(Me) ₂	H	3ac	78
13 ^c	6-Me	2,5-(Me) ₂	H	3bc	85
14 ^c	6-Cl	2,5-(Me) ₂	H	3cc	88
15 ^c	6-Br	2,5-(Me) ₂	H	3dc	86
16 ^c	7-OMe	2,5-(Me) ₂	H	3ec	91
17 ^c	8-OMe	2,5-(Me) ₂	H	3fc	85
18 ^c	6,8-(Cl) ₂	2,5-(Me) ₂	H	3gc	90
19 ^c	6,8-(Br) ₂	2,5-(Me) ₂	H	3hc	87
20 ^c	naphthyl	2,5-(Me) ₂	H	3ic	82
21	H	2,4-(Me) ₂ -3-Et	H	3ad	92
22	6-Me	2,4-(Me) ₂ -3-Et	H	3bd	89
23	6-Cl	2,4-(Me) ₂ -3-Et	H	3cd	92
24	6-Br	2,4-(Me) ₂ -3-Et	H	3dd	87
25	7-OMe	2,4-(Me) ₂ -3-Et	H	3ed	92
26	6,8-(Cl) ₂	2,4-(Me) ₂ -3-Et	H	3gd	86
27	6,8-(Br) ₂	2,4-(Me) ₂ -3-Et	H	3hd	75
28	H	H	H	3ae	77
29	H	H	Me	3af	73
30	H	2-COOH	H	—	NR ^d

^a Reactions were performed with **1a** (1.0 mmol) and **2a** (1.0 mmol) in the CH₂Cl₂ (10 mL). ^b Isolated yield. ^c The reaction was performed with Sc(OTf)₃ (5%) at 45 °C. ^d NR=No reaction.



Scheme 1. Scaled-up experiment of the one-pot reaction.




Figure 3. X-ray crystal structure of compound **3fa** (CCDC 2167896).

Table 3. In Vitro Fungicidal Activity of Target Compounds against Phytopathogens ^{a-c}.

Compound	A	B	C	D	E	F
3aa	31 ± 0	24 ± 0	<10	26 ± 3	64 ± 1	17 ± 1
3ba	25 ± 3	28 ± 0	<10	19 ± 2	58 ± 2	15 ± 0
3ca	<10	<10	<10	16 ± 1	44 ± 1	<10
3da	20 ± 1	21 ± 0	<10	14 ± 0	54 ± 1	<10
3ea	27 ± 1	24 ± 1	<10	14 ± 0	47 ± 0	21 ± 0
3fa	<10	<10	<10	<10	50 ± 1	<10
3ga	37 ± 2	73 ± 1	<10	22 ± 1	54 ± 0	21 ± 1
3ha	59 ± 2	36 ± 1	<10	55 ± 1	64 ± 0	79 ± 0
3ia	20 ± 0	17 ± 0	<10	29 ± 0	53 ± 1	43 ± 1
3ab	75 ± 3	67 ± 1	45 ± 2	74 ± 0	86 ± 2	64 ± 0
3ac	77 ± 0	<10	<10	77 ± 0	54 ± 1	82 ± 1
3bc	36 ± 1	48 ± 1	<10	40 ± 2	47 ± 0	20 ± 0
3cc	47 ± 3	56 ± 1	<10	55 ± 1	70 ± 0	61 ± 1
3dc	34 ± 0	42 ± 0	<10	46 ± 1	61 ± 1	29 ± 1
3ec	40 ± 0	49 ± 0	28 ± 0	51 ± 0	58 ± 0	40 ± 1
3fc	53 ± 2	45 ± 0	24 ± 0	46 ± 0	49 ± 0	45 ± 1
3gc	64 ± 1	56 ± 0	47 ± 0	56 ± 0	80 ± 2	50 ± 2
3hc	60 ± 2	50 ± 0	45 ± 1	43 ± 1	60 ± 1	32 ± 0
3ic	28 ± 1	24 ± 0	20 ± 0	33 ± 1	54 ± 1	15 ± 1
3ad	97 ± 0	84 ± 2	87 ± 0	82 ± 0	98 ± 1	88 ± 1
3bd	95 ± 0	88 ± 0	86 ± 1	62 ± 1	78 ± 2	85 ± 1
3cd	94 ± 2	69 ± 1	76 ± 1	62 ± 1	86 ± 1	57 ± 1
3dd	76 ± 2	58 ± 1	35 ± 1	47 ± 3	54 ± 1	35 ± 3
3ed	64 ± 2	73 ± 1	71 ± 1	52 ± 1	74 ± 1	33 ± 1
3gd	87 ± 2	93 ± 1	62 ± 2	94 ± 1	100	87 ± 1
3hd	89 ± 2	84 ± 1	53 ± 1	55 ± 0	100	88 ± 1
triadimefon	45 ± 1	41 ± 1	25 ± 1	85 ± 1	70 ± 1	30 ± 1

^a A: *Fusarium graminearum* (from corn), B: *Fusarium oxysporum*, C: *Fusarium graminearum* (from wheat), D: *Fusarium moniliforme*, E: *Rhizoctonia solani* Kuhn, F: *Phytophthora parasitica* var. *nicotianae*. ^b Values are means of three replicates. ^c The compounds exhibited a certain degree of fungicidal activity at a concentration of 500 µg/mL.

The in vitro fungicidal activity of the title compounds against six phytopathogens showed that the substituents have a great impact on the activity. Overall, the fungicidal activity of 3-ethyl-2,4-dimethyl-1H-pyrrole derivatives (**3ad**, **3bd**, **3cd**, **3gd**, and **3hd**) showed generally higher inhibition against the tested fungi than other substituted pyrrole derivatives.

Several compounds with higher preliminary antifungal activities at a concentration of 500 µg/mL were selected for determination of the median effective concentration (EC₅₀) values. As shown in Table 4, four compounds displayed good fungicidal activity against *R. solani* Kuhn. Among them, compound **3cd** was the most potent and had the EC₅₀ values

of 10.9 $\mu\text{g/mL}$. The results indicated that most of the coumarin derivatives containing α -trifluoromethylated tertiary alcohols exhibited good fungicidal activity.

Table 4. In Vitro Potency (EC_{50}) of Compounds with Higher Preliminary Activities ^a.

Fungicidal	Compound	Regression Equation	R ²	EC ₅₀ ($\mu\text{g/mL}$)
<i>F. graminearum</i>	3ad	$y = 0.401x + 1.007$	0.941	54.4
	3bd	$y = 0.445x + 0.930$	0.930	107.8
	triadimefon	$y = 0.346x + 1.181$	0.974	10.7
<i>F. oxysporum</i>	3hd	$y = 0.434x + 0.941$	0.947	96.7
	triadimefon	$y = 0.498x + 1.181$	0.990	42.9
<i>F. moniliforme</i>	3gd	$y = 0.654x + 1.182$	0.937	90.9
	triadimefon	$y = 0.234x + 1.194$	0.977	1.1
<i>R. solani</i> Kuhn.	3ad	$y = 0.317x + 1.032$	0.971	21.0
	3cd	$y = 0.226x + 0.944$	0.985	10.9
	3gd	$y = 0.321x + 1.065$	0.979	17.4
	3hd	$y = 0.339x + 1.075$	0.993	20.2
<i>P. parasitica</i> var <i>nicotianae</i>	triadimefon	$y = 0.329x + 1.227$	0.974	6.1
	3gd	$y = 0.616x + 1.074$	0.994	117.0
	3hd	$y = 0.440x + 1.027$	0.964	63.4
	triadimefon	$y = 0.248x + 0.745$	0.984	102.3

^a Values are means of three replicates.

Studies have reported that coumarin compounds can bind with the groove of chitinase and revealed better fungal inhibitory activity [43]. The molecular docking of the compound 3cd with 1W9U was conducted to explore the probable interaction with chitinase, and argifin was used as the standard of comparison. As can be seen from Figure 4, compared with argifin, the coumarin derivative 3cd shows some similar amino acid residues interacting with the receptor. For instance, TYR 245 formed a strong hydrogen bond with the fluorine that emerged as a hydrogen bond donor in the title compound. Then, another hydrogen bond appeared between the hydrogen in the pyrrole ring and ASP 246. It is worth noting that the target compound bonds to GLU 177 by a strong hydrogen bond, while argifin bonds to GLU 177 by the Van der Waals force. Although 3cd does not bind to GLU 178 by hydrogen bond as argifin does, it also binds to GLU 178 by Pi-Pi stacked interaction. Concurrently, the title compound 3cd connected with the TRP52, PHE76, GLY136, TRP137, PHE251, and TRP384 residues, which also formed weak interactions with the chitinase inhibitor argifin. As can be seen from the above results, our synthesized coumarin compounds are expected to be novel chitinase inhibitors, and the relative work is on the way.




Figure 4. Cont.




Figure 4. Docking modes of 3cd (A) and inhibitor argifin (B) with 1W9U.

3. Materials and Methods

3.1. Chemicals and Instruments

All chemicals, except 3-(trifluoroacetyl)coumarin 1, which was synthesized according our reported procedure, were purchased from commercial sources and used without further purification. ^1H NMR, ^{19}F NMR, and ^{13}C NMR spectra were obtained using a Bruker DPX-400 spectrometer (Bruker Technologies Co., Karlsruhe, Germany) in CDCl_3 or DMSO solution with TMS as an internal standard. HR-MS(APCI) spectra were performed using a Waters Q-ToF MicroTM instrument (Thermo Fisher Scientific, Waltham, Massachusetts, USA), and X-rays were measured at 293 K on a Rigaku RAXIAS-IV type diffractometer (Bruker Technologies Co., Karlsruhe, Germany). Most reaction yields, except compound 3fa, were not optimized. CCDC 2,167,896 contains the supplementary crystallographic data for this paper (Table S1 in the Supplement Materials). These data may be obtained free of charge via <http://www.ccdc.cam.ac.uk>; access on 15 November 2022.

3.1.1. General Procedure for the Preparation of Compounds 3aa–3af

A mixture of 3-(trifluoroacetyl)coumarin (1.0 mmol) and pyrrole (1.0 mmol) was stirred in methylene chloride (10 mL) at room temperature. After completion of the reaction, the mixture was concentrated under vacuum to yield the crude product, which was further purified by column chromatography.

To a mixture of 3-(trifluoroacetyl)coumarin (1.0 mmol) and pyrrole (1.0 mmol) in methylene chloride (10 mL) was added $\text{Sc}(\text{OTf})_3$ (5%), and the resulting mixture was heated under reflux. After completion of the reaction, the mixture was concentrated under vacuum to yield the crude product, which was further purified by column chromatography.

3.1.2. Compounds Data

3-(2,2,2-Trifluoro-1-hydroxy-1-(5-methyl-1H-pyrrol-2-yl)ethyl)-2H-chromen-2-one (3aa): Light Brown solid, mp: 134.5–135.6 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.43 (s, 1H), 7.87 (s, 1H), 7.61 (t, $J = 7.8$ Hz, 1H), 7.52 (d, $J = 7.7$ Hz, 1H), 7.40–7.32 (m, 2H), 7.28 (s, 1H), 6.25 (s, 1H), 5.92 (s, 1H), 2.26 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 162.47 (C=O), 153.22, 145.16, 133.21, 129.12, 128.97, 125.29, 124.49 (q, $J = 286.6$ Hz, C- CF_3), 123.50, 122.35, 118.39, 116.60, 108.76, 106.82, δ 76.71 (q, $J = 31.3$ Hz, CF_3), 12.96. ^{19}F NMR (376 MHz, CDCl_3) δ -78.01(CF_3). HRMS (APCI): m/z calculated for $\text{C}_{16}\text{H}_{11}\text{F}_3\text{NO}_3$ $[\text{M}-\text{H}]^-$ 322.0691, found: 322.0685.

6-Methyl-3-(2,2,2-trifluoro-1-hydroxy-1-(5-methyl-1H-pyrrol-2-yl)ethyl)-2H-chromen-2-one (3ba): Light yellow solid, mp: 207.9–208.7 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.46 (s, 1H), 8.29 (s, 1H), 7.70 (s, 1H), 7.48 (d, $J = 8.5$ Hz, 1H), 7.33 (d, $J = 8.4$ Hz, 1H), 7.16 (s, 1H), 6.01 (s, 1H), 5.69 (s, 1H), 2.38 (s, 3H), 2.12 (s, 3H). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ

158.48(C=O), 152.02, 143.74, 134.41, 133.92, 129.46, 128.37, 125.48, 125.30 (q, $J = 287.4$ Hz, C-CF₃), 124.53, 118.64, 115.98, 107.68, 105.78, δ 74.36 (q, $J = 29.9$ Hz, CF₃), 20.68, 13.09. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -74.08(CF₃). HRMS (APCI): m/z calculated for C₁₇H₁₃F₃NO₃ [M-H]⁻ 336.0848, found: 336.0833.

6-Chloro-3-(2,2,2-trifluoro-1-hydroxy-1-(5-methyl-1H-pyrrol-2-yl)ethyl)-2H-chromen-2-one (**3ca**): White solid, mp: 235.9–236.5 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.43 (s, 1H), 8.45 (s, 1H), 8.13 (d, $J = 2.5$ Hz, 1H), 7.71 (dd, $J = 8.8, 2.6$ Hz, 1H), 7.48 (d, $J = 8.9$ Hz, 1H), 7.20 (s, 1H), 6.01 (s, 1H), 5.69 (s, 1H), 2.11 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 157.47(C=O), 152.62, 142.80, 132.58, 129.50, 128.95, 128.81, 128.38, 126.01, 125.35, 125.20(q, $J = 287.4$ Hz, C-CF₃), 120.41, 118.23, 107.69, 105.86, 74.07(q, $J = 30.1$ Hz, CF₃), 13.09. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -73.76(CF₃). HRMS (APCI): m/z calculated for C₁₆H₁₀ClF₃NO₃ [M-H]⁻ 356.0301, found: 356.0295.

6-Bromo-3-(2,2,2-trifluoro-1-hydroxy-1-(5-methyl-1H-pyrrol-2-yl)ethyl)-2H-chromen-2-one (**3da**): Cyan solid, mp: 236.5–236.9 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.41 (s, 1H), 8.43 (s, 1H), 8.24 (d, $J = 2.3$ Hz, 1H), 7.81 (dd, $J = 8.8, 2.4$ Hz, 1H), 7.40 (d, $J = 8.8$ Hz, 1H), 7.17 (s, 1H), 6.01 (s, 1H), 5.68 (s, 1H), 2.11 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 157.41(C=O), 153.01, 142.70, 135.33, 131.94, 128.36, 125.94, 125.34, 125.20 (q, $J = 287.3$ Hz, C-CF₃), 120.90, 118.50, 116.58, 107.67, 105.84, 74.07 (q, $J = 30.3$ Hz, CF₃), 13.09. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -73.78(CF₃). HRMS (APCI): m/z calculated for C₁₆H₁₀BrF₃NO₃ [M-H]⁻ 399.9796, found: 399.9782.

7-Methoxy-3-(2,2,2-trifluoro-1-hydroxy-1-(5-methyl-1H-pyrrol-2-yl)ethyl)-2H-chromen-2-one (**3ea**): White solid, mp: 160.5–161.8 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.45 (s, 1H), 8.27 (s, 1H), 7.82 (d, $J = 8.6$ Hz, 1H), 7.09 (s, 1H), 7.04 (d, $J = 2.4$ Hz, 1H), 6.99 (dd, $J = 8.6, 2.4$ Hz, 1H), 6.01 (s, 1H), 5.68 (s, 1H), 3.88 (s, 3H), 2.12 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 163.53(C=O), 158.79, 155.83, 143.94, 130.98, 128.30, 125.65, 125.40 (q, $J = 287.5$ Hz, C-CF₃), 120.75, 113.20, 112.48, 107.63, 105.73, 100.51, 74.31 (q, $J = 60.1, 30.1$ Hz, CF₃), 56.52, 13.10. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -74.31(CF₃). HRMS (APCI): m/z calculated for C₁₇H₁₃F₃NO₄ [M-H]⁻ 352.0797, found: 352.0783.

8-Methoxy-3-(2,2,2-trifluoro-1-hydroxy-1-(5-methyl-1H-pyrrol-2-yl)ethyl)-2H-chromen-2-one (**3fa**): Pink solid, mp: 198.1–198.6 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.44 (s, 1H), 8.36 (s, 1H), 7.46 (dd, $J = 7.1, 1.9$ Hz, 1H), 7.40–7.29 (m, 2H), 7.15 (d, $J = 0.9$ Hz, 1H), 6.01 (s, 1H), 5.69 (s, 1H), 3.93 (s, 3H), 2.11 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.02(C=O), 147.06, 145.28, 142.86, 128.75, 125.17, 124.47 (q, $J = 286.7$ Hz, C-CF₃), 123.46, 122.50, 120.22, 119.05, 114.72, 108.69, 106.77, 76.68 (q, $J = 31.3$ Hz, CF₃), 56.35, 12.93. ¹⁹F NMR (376 MHz, CDCl₃) δ -78.04(CF₃). HRMS (APCI): m/z calculated for C₁₇H₁₃F₃NO₄ [M-H]⁻ 352.0797, found: 352.0791.

6,8-Dichloro-3-(2,2,2-trifluoro-1-hydroxy-1-(5-methyl-1H-pyrrol-2-yl)ethyl)-2H-chromen-2-one (**3ga**): Light yellow solid, mp: 168.5–169.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 7.76 (s, 1H), 7.63 (d, $J = 2.3$ Hz, 1H), 7.43 (d, $J = 2.3$ Hz, 1H), 6.88 (s, 1H), 6.22 (s, 1H), 5.91 (s, 1H), 2.26 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.77(C=O), 147.55, 143.78, 132.98, 130.53, 129.39, 128.53, 126.86, 124.71, 124.24 (q, $J = 286.7$ Hz, C-CF₃), 122.72, 122.63, 120.13, 119.98, 76.73 (q, $J = 31.5$ Hz, CF₃), 12.92. ¹⁹F NMR (376 MHz, CDCl₃) δ -77.71(CF₃). HRMS (APCI): m/z calculated for C₁₆H₉Cl₂F₃NO₃ [M-H]⁻ 389.9912, found: 389.9903.

6,8-Dibromo-3-(2,2,2-trifluoro-1-hydroxy-1-(5-methyl-1H-pyrrol-2-yl)ethyl)-2H-chromen-2-one (**3ha**): Cyan solid, mp: 162.1–163.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.47 (s, 1H), 7.92 (d, $J = 2.2$ Hz, 1H), 7.74 (s, 1H), 7.61 (d, $J = 2.2$ Hz, 1H), 6.87 (s, 1H), 6.23 (s, 1H), 5.91 (s, 1H), 2.26 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.85(C=O), 149.06, 143.75, 138.01, 130.57, 129.38, 124.64, 124.25 (q, $J = 287.0$ Hz, C-CF₃), 122.74, 120.53, 117.88, 111.52, 108.96, 106.95, 76.69 (q, $J = 31.7$ Hz, CF₃), 12.95. ¹⁹F NMR (376 MHz, CDCl₃) δ -77.71(CF₃). HRMS (APCI): m/z calculated for C₁₆H₉Br₂F₃NO₃ [M-H]⁻ 479.8881, found: 479.8868.

3-(2,2,2-Trifluoro-1-hydroxy-1-(5-methyl-1H-pyrrol-2-yl)ethyl)-2H-benzo[h]chromen-2-one (**3ia**): Tawny solid, mp: 192.0–192.9 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.68 (s, 1H), 8.54 (s, 1H), 8.12–8.00 (m, 2H), 7.91 (d, $J = 8.1$ Hz, 1H), 7.71 (t, $J = 7.6$ Hz, 1H), 7.60 (t, $J = 7.5$ Hz, 1H), 7.51–7.40 (m, 2H), 7.26 (s, 1H), 6.39 (s, 1H), 6.01 (s, 1H), 2.28 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.56(C=O), 153.31, 141.04, 134.78, 130.47, 129.16, 129.01, 128.97,

128.90, 126.70, 124.65 (q, $J = 286.8$ Hz, C-CF₃), 123.60, 121.48, 121.04, 116.24, 112.91, 108.65, 107.03, 76.95 (q, $J = 31.2$ Hz, CF₃), 12.97. ¹⁹F NMR (376 MHz, CDCl₃) δ -78.07(CF₃). HRMS (APCI): m/z calculated for C₂₀H₁₃F₃NO₃ [M-H]⁻ 372.0848, found: 372.0838.

3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3ab**): Pink solid, mp: 131.7–132.8 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.18 (s, 1H), 7.78 (s, 1H), 7.57–7.47 (m, 2H), 7.33–7.27 (m, 2H), 7.17 (s, 1H), 6.26 (s, 1H), 5.62 (d, $J = 3.1$ Hz, 1H), 2.14 (s, 3H), 1.78 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.74(C=O), 153.09, 142.52, 133.01, 129.11, 128.81, 127.39 (q, $J = 286.7$ Hz, C-CF₃), 127.25, 125.31, 123.10, 118.92, 118.19, 118.01, 116.66, 110.71, 76.50 (q, $J = 31.3$ Hz, CF₃), 12.91, 12.48. ¹⁹F NMR (376 MHz, CDCl₃) δ -75.55(CF₃). HRMS (APCI): m/z calculated for C₁₇H₁₃F₃NO₃ [M-H]⁻ 336.0848, found: 336.0833.

3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl)-8-methoxy-2H-chromen-2-one (**3fb**): Orange solid, mp: 67.1–68.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.24 (s, 1H), 7.83 (s, 1H), 7.33–7.26 (m, 2H), 7.14 (dd, $J = 7.1, 5.4$ Hz, 2H), 6.40 (s, 1H), 5.69 (d, $J = 3.1$ Hz, 1H), 3.98 (s, 3H), 2.23 (s, 3H), 1.86 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.34(C=O), 147.08, 142.74, 127.28, 125.25, 124.58 (q, $J = 286.4$ Hz, C-CF₃), 123.27, 120.33, 120.24, 118.91, 118.86, 118.05, 114.62, 110.69, 76.54 (q, $J = 31.1$ Hz, CF₃), 56.31, 12.87, 12.50. ¹⁹F NMR (376 MHz, CDCl₃) δ -75.57(CF₃). HRMS (APCI): m/z calculated for C₁₈H₁₅F₃NO₃ [M-OH]⁺ 350.0999, found: 350.1008.

3-(1-(2,5-Dimethyl-1H-pyrrol-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3ac**): Cyan solid, mp: 109.7–110.8 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.86 (s, 1H), 7.73 (s, 1H), 7.59 (t, $J = 8.5$ Hz, 1H), 7.50 (d, $J = 7.7$ Hz, 1H), 7.40–7.28 (m, 2H), 6.59 (s, 1H), 5.90 (s, 1H), 2.21 (s, 3H), 2.16 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.19(C=O), 153.26, 144.34, 132.76, 128.94, 125.92, 125.34 (q, $J = 287.4$ Hz, C-CF₃), 125.22, 125.10, 124.76, 121.07, 118.59, 116.54, 114.97, 106.45, 77.99 (q, $J = 30.0$ Hz, CF₃), 12.96, 12.80. ¹⁹F NMR (376 MHz, CDCl₃) δ -76.82(CF₃). HRMS (APCI): m/z calculated for C₁₇H₁₃F₃NO₂ [M-OH]⁺ 320.0893, found: 320.0917.

3-(1-(2,5-Dimethyl-1H-pyrrol-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-6-methyl-2H-chromen-2-one (**3bc**): White solid, mp: 161.2–162.0 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.75 (s, 1H), 7.67 (s, 1H), 7.39 (dd, $J = 8.5, 1.3$ Hz, 1H), 7.29 (d, $J = 7.1$ Hz, 1H), 6.61 (s, 1H), 5.89 (s, 1H), 2.39 (s, 1H), 2.21 (s, 1H), 2.17 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 162.34(C=O), 151.42, 144.19, 134.87, 133.75, 128.62, 125.84, 125.35 (q, $J = 287.5$ Hz, C-CF₃), 125.03, 124.63, 118.35, 116.24, 115.17, 106.54, 77.96 (q, $J = 30.0$ Hz, CF₃), 20.71, 12.99, 12.82. ¹⁹F NMR (376 MHz, CDCl₃) δ -76.88(CF₃). HRMS (APCI): m/z calculated for C₁₈H₁₅F₃NO₃ [M-H]⁻ 350.1004, found: 350.0989.

6-Chloro-3-(1-(2,5-dimethyl-1H-pyrrol-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3cc**): Yellow solid, mp: 145.2–146.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 7.66 (s, 1H), 7.52 (dd, $J = 10.9, 2.1$ Hz, 2H), 7.32 (d, $J = 8.6$ Hz, 1H), 6.39 (s, 1H), 5.87 (s, 1H), 2.20 (s, 3H), 2.15 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 157.47(C=O), 152.62, 142.80, 132.58, 129.50, 128.95, 126.01, 125.35, 125.18 (q, $J = 287.1$ Hz, C-CF₃), 120.93, 120.41, 118.23, 107.69, 105.86, 78.00 (q, $J = 30.0$ Hz, CF₃), 12.95, 12.77. ¹⁹F NMR (376 MHz, CDCl₃) δ -76.72(CF₃). HRMS (APCI): m/z calculated for C₁₇H₁₂ClF₃NO₃ [M-H]⁻ 370.0458, found: 370.0449.

6-Bromo-3-(1-(2,5-dimethyl-1H-pyrrol-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3dc**): Brown solid, mp: 168.6–170.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (s, 1H), 7.65 (dd, $J = 6.7, 2.9$ Hz, 3H), 7.24 (s, 1H), 6.32 (s, 1H), 5.85 (s, 1H), 2.19 (s, 3H), 2.15 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.34(C=O), 152.10, 142.81, 135.42, 131.12, 126.64, 125.86, 125.16 (q, $J = 287.7$ Hz, C-CF₃), 124.88, 120.07, 118.28, 117.68, 114.78, 106.45, 77.97 (q, $J = 30.0$ Hz, CF₃), 13.02, 12.82. ¹⁹F NMR (376 MHz, CDCl₃) δ -76.70(CF₃). HRMS (APCI): m/z calculated for C₁₇H₁₂BrF₃NO₃ [M-H]⁻ 413.9953, found: 413.9936.

3-(1-(2,5-Dimethyl-1H-pyrrol-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-7-methoxy-2H-chromen-2-one (**3ec**): Yellow solid, mp: 80.1–81.7 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.28 (s, 1H), 7.81 (s, 1H), 7.24 (m, 1H), 7.08 (s, 1H), 6.38 (s, 1H), 5.66 (s, 1H), 3.93 (s, 3H), 2.18 (s, 3H), 1.84 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.59(C=O), 147.06, 144.21, 126.74, 125.88, 125.51, 125.49 (q, $J = 287.5$ Hz, C-CF₃), 124.90, 124.61, 123.89, 120.06, 115.11, 114.29, 106.53, 77.89 (q, $J = 29.9$ Hz, CF₃), 56.33, 13.00, 12.82. ¹⁹F NMR (376 MHz, CDCl₃) δ -76.86(CF₃). HRMS (APCI): m/z calculated for C₁₈H₁₅F₃NO₄ [M-H]⁻ 366.0953, found: 366.0941.

3-(1-(2,5-Dimethyl-1H-pyrrol-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-8-methoxy-2H-chromen-2-one (**3fc**): Cyan solid, mp: 79.8–81.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.72 (s, 1H), 7.69 (s, 1H), 7.23 (d, *J* = 7.9 Hz, 1H), 7.12 (d, *J* = 8.1 Hz, 1H), 7.06 (d, *J* = 7.8 Hz, 1H), 6.55 (s, 1H), 5.78 (d, *J* = 82.7 Hz, 1H), 4.02–3.88 (m, 1H), 2.21 (s, 1H), 2.17 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 161.59(C=O), 147.06, 144.21, 125.88, 125.51, 125.49 (q, *J* = 287.5 Hz, C-CF₃), 124.90, 124.61, 123.89, 120.06, 119.27, 115.11, 114.29, 106.53, 77.89 (q, *J* = 29.9 Hz, CF₃), 56.33, 13.00, 12.82. ¹⁹F NMR (376 MHz, CDCl₃) δ -76.86(CF₃). HRMS (APCI): *m/z* calculated for C₁₈H₁₅F₃NO₄ [M-H]⁻ 366.0953, found: 366.0941.

6,8-Dichloro-3-(1-(2,5-dimethyl-1H-pyrrol-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3gc**): Tawny solid, mp: 119.1–120.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 1H), 7.68–7.60 (m, 2H), 7.42 (d, *J* = 2.3 Hz, 1H), 6.16 (s, 1H), 5.86 (s, 1H), 2.21 (s, 3H), 2.17 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.74(C=O), 150.72, 143.67, 133.55, 130.24, 127.58, 126.66, 125.91, 125.05 (q, *J* = 287.4 Hz, C-CF₃), 124.67, 122.56, 120.36, 115.05, 108.26, 77.96 (q, *J* = 30.2 Hz, CF₃), 12.98, 12.78. ¹⁹F NMR (376 MHz, CDCl₃) δ -76.73(CF₃). HRMS (APCI): *m/z* calculated for C₁₇H₁₁Cl₂F₃NO₃ [M-H]⁻ 404.0068, found: 404.0052.

6,8-Dibromo-3-(1-(2,5-dimethyl-1H-pyrrol-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3hc**): Yellow solid, mp: 172.6–174.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 2.1 Hz, 1H), 7.80 (s, 1H), 7.63–7.61 (m, 2H), 6.19 (s, 1H), 5.86 (s, 1H), 2.21 (s, 3H), 2.16 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.40(C=O), 149.16, 142.67, 138.06, 129.36, 127.48, 125.53 (q, *J* = 287.5 Hz, C-CF₃), 125.00, 120.79, 120.16, 117.60, 114.46, 111.06, 106.34, 77.91 (q, *J* = 30.1 Hz, CF₃), 13.00, 12.80. ¹⁹F NMR (376 MHz, CDCl₃) δ -77.71 (CF₃). HRMS (APCI): *m/z* calculated for C₁₇H₁₁Br₂F₃NO₂ [M-OH]⁺ 477.9083, found: 477.9106.

3-(1-(2,5-Dimethyl-1H-pyrrol-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-benzo[h]chromen-2-one (**3ic**): Khaki solid, mp: 168.6–170.4 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.69 (s, 1H), 9.38 (s, 1H), 8.67 (d, *J* = 8.5 Hz, 1H), 8.49 (d, *J* = 9.1 Hz, 1H), 8.35 (d, *J* = 8.1 Hz, 1H), 8.05 (t, *J* = 7.7 Hz, 1H), 7.97–7.83 (m, 2H), 6.16 (s, 1H), 2.47 (s, 3H), 2.30 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.13(C=O), 153.25, 139.80, 134.20, 133.03, 130.48, 129.16, 128.63, 128.29, 127.58 (q, *J* = 294.1 Hz, C-CF₃), 126.51, 125.94, 124.26, 121.52, 116.44, 115.18, 112.99, 106.55, 78.16 (q, *J* = 30.2 Hz, CF₃), 13.11, 12.90. ¹⁹F NMR (376 MHz, CDCl₃) δ -76.70(CF₃). HRMS (APCI): *m/z* calculated for C₂₁H₁₅F₃NO₃ [M-H]⁻ 386.1004, found: 386.0996.

3-(1-(4-Ethyl-3,5-dimethyl-1H-pyrrol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3ad**): Yellow solid, mp: 162.9–163.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.10 (s, 1H), 7.85 (s, 1H), 7.65–7.56 (m, 2H), 7.38 (dd, *J* = 14.8, 7.6 Hz, 2H), 6.35 (s, 1H), 2.34 (q, *J* = 7.4 Hz, 2H), 2.19 (s, 3H), 1.83 (s, 3H), 1.02 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.74(C=O), 153.14, 142.61, 132.95, 129.10, 126.09, 125.27, 124.72 (q, *J* = 272.1 Hz, C-CF₃), 123.39, 123.26, 122.46, 118.28, 118.08, 116.68, 76.68 (q, *J* = 30.8 Hz, CF₃), 17.51, 15.56, 11.19, 10.08. ¹⁹F NMR (376 MHz, CDCl₃) δ -75.42(CF₃). HRMS (APCI): *m/z* calculated for C₁₉H₁₇F₃NO₃ [M-H]⁻ 364.1161, found: 364.1150.

3-(1-(4-Ethyl-3,5-dimethyl-1H-pyrrol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl)-6-methyl-2H-chromen-2-one (**3bd**): Yellow solid, mp: 160.8–161.9 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (s, 1H), 7.75 (s, 1H), 7.37 (m, 2H), 7.23 (d, *J* = 4.1 Hz, 1H), 6.39 (s, 1H), 2.42 (s, 3H), 2.36 (q, *J* = 7.5 Hz, 2H), 2.15 (s, 3H), 1.78 (s, 3H), 0.98 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.01(C=O), 151.29, 142.67, 135.15, 134.03, 128.82, 124.68 (q, *J* = 286.8 Hz, C-CF₃), 123.18, 123.13, 122.43, 118.17, 118.04, 116.62, 116.35, 76.69 (q, *J* = 30.7 Hz, CF₃), 20.75, 17.51, 15.57, 11.19, 10.06. ¹⁹F NMR (376 MHz, CDCl₃) δ -75.46(CF₃). HRMS (APCI): *m/z* calculated for C₂₀H₁₉F₃NO₃ [M-H]⁻ 378.1317, found: 378.1299.

6-Chloro-3-(1-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3cd**): Light yellow solid, mp: 169.4–170.1 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.76 (s, 1H), 8.26 (s, 1H), 8.10 (d, *J* = 2.3 Hz, 1H), 7.68 (d, *J* = 2.4 Hz, 1H), 7.44 (d, *J* = 8.9 Hz, 1H), 6.97 (s, 1H), 2.20 (q, *J* = 7.3 Hz, 2H), 2.04 (s, 3H), 1.74 (s, 3H), 0.91 (d, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 157.32(C=O), 152.24, 140.16, 132.55, 129.04, 128.94, 126.11, 125.42 (q, *J* = 287.8 Hz, C-CF₃), 122.89, 121.14, 120.69, 120.03, 118.87, 118.26, 74.98 (q, *J* = 30.0 Hz, CF₃), 17.43, 16.19, 11.09, 10.04. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -73.50(CF₃). HRMS (APCI): *m/z* calculated for C₁₉H₁₆ClF₃NO₃ [M-H]⁻ 398.0771, found: 398.0751.

6-Bromo-3-(1-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3dd**): Yellow solid, mp: 168.6–169.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.06 (s, 1H), 7.77–7.67 (m, 2H), 7.27 (d, *J* = 9.6 Hz, 1H), 6.14 (s, 1H), 2.33 (q, *J* = 7.6 Hz, 2H), 2.18 (s, 3H), 1.81 (s, 3H), 1.01 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.99 (C=O), 151.97, 141.31, 135.69, 131.29, 124.67, 124.51 (q, *J* = 286.8 Hz, C-CF₃), 123.48, 122.54, 119.76, 118.36, 117.90, 117.71, 116.77, 76.66 (q, *J* = 30.9 Hz, CF₃), 17.49, 15.55, 11.20, 10.08. ¹⁹F NMR (376 MHz, CDCl₃) δ -75.34(CF₃). HRMS (APCI): *m/z* calculated for C₁₉H₁₆BrF₃NO₃ [M-H]⁻ 442.0266, found: 442.0243.

3-(1-(4-Ethyl-3,5-dimethyl-1H-pyrrol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl)-7-methoxy-2H-chromen-2-one (**3ed**): Cyan solid, mp: 160.4–161.1 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.77 (s, 1H), 8.18 (s, 1H), 7.86 (d, *J* = 8.6 Hz, 1H), 7.03–6.97 (m, 2H), 6.79 (s, 1H), 3.86 (s, 3H), 2.25–2.19 (m, 2H), 2.06 (s, 3H), 1.74 (s, 3H), 0.93 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 163.39(C=O), 158.27, 155.58, 141.29, 131.12, 125.63 (d, *J* = 290.7 Hz, C-CF₃), 122.61, 121.36, 120.53, 119.44, 114.52, 113.20, 112.15, 100.56, 74.99 (d, *J* = 29.0 Hz, CF₃), 56.50, 17.50, 16.24, 11.14, 10.10. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -75.42(CF₃). HRMS (APCI): *m/z* calculated for C₂₀H₁₉F₃NO₄ [M-H]⁻ 394.1266, found: 394.1247.

6,8-Dichloro-3-(1-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3gd**): Dark yellow solid, mp: 145.8–146.5 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.77 (s, 1H), 8.33 (s, 1H), 8.17 (d, *J* = 2.3 Hz, 1H), 8.00 (d, *J* = 2.3 Hz, 1H), 7.04 (s, 1H), 2.23 (q, *J* = 7.4 Hz, 2H), 2.06 (s, 3H), 1.80 (s, 3H), 0.93 (d, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 156.23(C=O), 148.16, 140.16, 131.95, 128.85, 128.31, 126.98, 125.38 (q, *J* = 287.6 Hz, C-CF₃), 122.98, 121.15, 120.88, 118.73, 115.10, 74.95 (q, *J* = 29.7 Hz, CF₃), 17.45, 16.20, 11.13, 11.09, 10.14. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -73.30. HRMS (APCI): *m/z* calculated for C₁₉H₁₅Cl₂F₃NO₃ [M-H]⁻ 432.0381, found: 432.0357.

6,8-Dibromo-3-(1-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl)-2H-chromen-2-one (**3hd**): Dark yellow solid, mp: 142.2–142.9 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.97 (s, 1H), 7.88 (d, *J* = 2.2 Hz, 1H), 7.65 (s, 1H), 7.60 (d, *J* = 2.2 Hz, 1H), 5.88 (s, 1H), 2.29–2.23 (m, 2H), 2.11 (s, 3H), 1.74 (s, 3H), 0.95 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 156.40(C=O), 149.64, 140.11, 137.24, 131.84, 126.84, 122.97, 122.54 (q, *J* = 287.5 Hz, C-CF₃), 120.69, 118.75, 116.78, 115.09, 110.16, 74.94 (q, *J* = 29.8 Hz, CF₃), 17.46, 16.21, 11.13, 11.09, 10.15. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -73.32(CF₃). HRMS (APCI): *m/z* calculated for C₁₉H₁₅Br₂F₃NO₃ [M-H]⁻ 521.9350, found: 521.9319.

3-(2,2,2-Trifluoro-1-hydroxy-1-(1H-pyrrol-2-yl)-ethyl)-2H-chromen-2-one (**3ae**): White solid, mp: 153.5–154.3 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 7.84 (s, 1H), 7.62 (t, *J* = 7.9 Hz, 1H), 7.50 (s, 1H), 7.44–7.34 (m, 3H), 7.26 (s, 1H), 6.86 (s, 1H), 6.40 (s, 1H), 6.27 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 162.44(C=O), 154.19, 146.88, 135.26, 129.13, 125.89, 125.20, 124.45 (q, *J* = 286.5 Hz, C-CF₃), 118.81, 118.33, 116.62, 110.00, 109.06, 108.40, 76.69 (q, *J* = 31.4 Hz, CF₃). ¹⁹F NMR (376 MHz, CDCl₃) δ -78.07(CF₃). HRMS (APCI): *m/z* calculated for C₁₅H₉F₃NO₂ [M-H]⁻ 308.0540, found: 308.0537.

3-(2,2,2-Trifluoro-1-hydroxy-1-(1-methyl-1H-pyrrol-2-yl)ethyl)-2H-chromen-2-one (**3af**): White solid, mp: 129.3–131.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.66–7.60 (m, 1H), 7.46–7.40 (m, 2H), 7.36–7.31 (m, 2H), 7.21 (s, 1H), 6.70–6.64 (m, 1H), 6.46 (s, 1H), 6.17–6.10 (m, 1H), 3.55 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.22 (C=O), 153.42, 146.17, 133.39, 129.06, 125.76, 125.35, 124.87, 124.71 (q, *J* = 287.8 Hz, C-CF₃), 122.31, 118.39, 116.69, 111.43, 106.56, 77.85 (q, *J* = 30.6 Hz, CF₃), 36.14. ¹⁹F NMR (376 MHz, CDCl₃) δ -77.07(CF₃). HRMS (APCI): *m/z* calculated for C₁₆H₁₁F₃NO₂ [M-OH]⁺ 306.0737, found: 306.0747.

3.2. In Vitro Antifungal Assay

Antifungal assays were performed against *F. graminearum* (from corn), *F. oxysporum*, *F. graminearum* (from wheat), *F. moniliforme*, *R. solani* Kuhn, and *P. parasitica* var *nicotianae* in vitro by the plate growth rate method. The synthesized compounds were dissolved in 2% DMSO to yield a 10 mg/mL stock solution. Then, each solution was added to sterile potato dextrose agar (PDA) to give final concentrations of 0.1 mg/mL. After the mixture was chilled, the mycelium of the fungi was transferred to the test plate and incubated at 26 °C. When the

mycelium of the fungi reached the edges of the control plate (without sample), the inhibitory index was calculated as follows: Inhibitory index (%) = $(D_b - D_a)/(D_b - D_c) \times 100\%$, where D_a is the colony diameter of the growth zone in the test plate, D_b is the colony diameter of the growth zone in the control plate, and D_c is the diameter of the mycelial disc. The median effective concentration (EC_{50}) of each compound with a significant fungicidal activity was further evaluated in three independent experiments. The statistical analyses were performed using SPSS software (IBM SPSS Statistic 26).

3.3. Molecular Docking

The molecular docking studies of compound **3cd** and triadimefon were performed with the assistance of Discovery Studio 2016 software and pymol. The crystal structure of Tre was acquired from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB code 2JF4). The ligand validoxylamine was extracted, and all water molecules were eliminated from this crystal complex. Libdock was applied for simulating and evaluating the interactions between the compounds and the target protein by an empirical scoring function.

4. Conclusions

In conclusion, we have developed a new and practical catalyst-free method for novel α -trifluoromethylated tertiary alcohols bearing coumarins at ambient temperature. This procedure means a promising approach for attaining these new heterocycles, since it applies mild and easily operational conditions (no special reagents, catalysts, or additives). Altogether, 29 new α -trifluoromethylated tertiary alcohols were synthesized in high to excellent yields. The crystal structure of compound **3fa** was studied by single-crystal XRD analysis. The biological activity of the α -trifluoromethylated tertiary alcohols was also tested in in vitro antifungal assays. The bioassay results indicated that the compounds showed broad-spectrum fungicidal activity in vitro.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules28010260/s1>, Figure S1: Molecular packing of compound **3fa** (CCDC 2167896); Table S1: The refinement information and crystallographic data of **3fa**; and Figures S2–S88: $^1\text{H-NMR}$, $^{13}\text{C-NMR}$ and $^{19}\text{F-NMR}$ spectra of compounds **3aa–3fa**. Figures S89–S117: HRMS spectra of compounds **3aa–3fa**.

Author Contributions: Conceptualization, S.J., L.W. and C.X.; Data curation, S.J.; Formal analysis, L.S.; Investigation, S.J., X.C., B.Z. and M.X.; Methodology, G.Y. and L.W.; Project administration, C.W.; Resources, C.X.; Supervision, L.F. and Z.P.; Writing—original draft, L.W.; Writing—review & editing, G.Y., L.W. and C.X. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Natural Science Foundation of Henan Province (222300420459(to C.X.), 222300420456(to G.Y.)), Science and Technology Agency of Henan Province (212102311067(to L.W.), 222102310243(to C.W.)), and Science and Technology Innovation Fund of Henan Agricultural University (KJCX2020A19(to L.W.)).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Shimizu, M.; Hiyama, T. Modern Synthetic Methods for Fluorine-Substituted Target Molecules. *Angew. Chem. Int. Ed.* **2005**, *44*, 214–231. [[CrossRef](#)]
2. Ma, J.; Cahard, D. Strategies for nucleophilic, electrophilic, and radical trifluoromethylations. *J. Fluor. Chem.* **2007**, *128*, 975–996. [[CrossRef](#)]
3. Hagmann, W.K. The Many Roles for Fluorine in Medicinal Chemistry. *J. Med. Chem.* **2008**, *51*, 4359–4369. [[CrossRef](#)] [[PubMed](#)]

4. Zheng, Y.; Ma, J.-A. Combination Catalysis in Enantioselective Trifluoromethylation. *Adv. Synth. Catal.* **2010**, *352*, 2745–2750. [[CrossRef](#)]
5. Liu, X.; Xu, C.; Wang, M.; Liu, Q. Trifluoromethyltrimethylsilane: Nucleophilic Trifluoromethylation and Beyond. *Chem. Rev.* **2015**, *115*, 683–730. [[CrossRef](#)] [[PubMed](#)]
6. Corbett, J.W.; Soo, S.K.; James, D.R.; Lisa, A.G.; Nicholas, A.M.; Lee, T.B.; Sharon, D.; Susan, J.; Ronald, M.K.; Beverly, C.C.; et al. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. *J. Med. Chem.* **2000**, *43*, 2019–2030. [[CrossRef](#)] [[PubMed](#)]
7. Sani, M.; Belotti, D.; Giavazzi, R.; Panzeri, W.; Volonterio, A.; Zanda, M. Synthesis and evaluation of stereopure α -trifluoromethylmalic hydroxamates as inhibitors of matrix metalloproteinases. *Tetrahedron Lett.* **2004**, *45*, 1611–1615. [[CrossRef](#)]
8. Betageri, R.; Zhang, Y.; Zindell, R.M.; Kuzmich, D.; Kirrane, T.M.; Bentzien, J.; Cardozo, M.; Capolino, A.J.; Fadra, T.N.; Nelson, R.M.; et al. Trifluoromethyl group as a pharmacophore: Effect of replacing a CF₃ group on binding and agonist activity of a glucocorticoid receptor ligand. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4761–4769. [[CrossRef](#)]
9. Caron, S.; Do, N.M.; Sieser, J.E.; Arpin, P.; Vazquez, E. Process Research and Development of an NK-1 Receptor Antagonist. Enantioselective Trifluoromethyl Addition to a Ketone in the Preparation of a Chiral Isochroman. *Org. Process Res. Dev.* **2007**, *11*, 1015–1024. [[CrossRef](#)]
10. Han, X.; Ouyang, W.; Liu, B.; Wang, W.; Tien, P.; Wu, S.; Zhou, H.-B. Enantioselective inhibition of reverse transcriptase (RT) of HIV-1 by non-racemic indole-based trifluoropropanoates developed by asymmetric catalysis using recyclable organocatalysts. *Org. Biomol. Chem.* **2013**, *11*, 8463–8475. [[CrossRef](#)]
11. Jiang, H.-X.; Zhuang, D.; Huang, Y.; Cao, X.-X.; Yao, J.-H.; Li, J.-Y.; Wang, J.-Y.; Zhang, C.; Jiang, B. Design, synthesis, and biological evaluation of novel trifluoromethyl indole derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. *Org. Biomol. Chem.* **2014**, *12*, 3446–3458.
12. Wang, J.; Sánchez-Roselló, M.; Aceña, J.L.; del Pozo, C.; Sorochinsky, A.E.; Fustero, S.; Soloshonok, V.A.; Liu, H. Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011). *Chem. Rev.* **2014**, *114*, 2432–2506. [[CrossRef](#)] [[PubMed](#)]
13. Inoue, M.; Sumii, Y.; Shibata, N. Contribution of Organofluorine Compounds to Pharmaceuticals. *ACS Omega* **2020**, *5*, 10633–10640. [[CrossRef](#)]
14. Aikawa, K.; Hioki, Y.; Mikami, K. Highly enantioselective alkynylation of trifluoropyruvate with alkynylsilanes catalyzed by the BINAP-Pd complex: Access to *o*-trifluoromethyl-substituted tertiary alcohols. *Org. Lett.* **2010**, *12*, 5716–5719. [[CrossRef](#)] [[PubMed](#)]
15. Lutete, L.M.; Miyamoto, T.; Ikemoto, T. Tertiary amino thiourea-catalyzed asymmetric cross aldol reaction of aryl methyl ketones with aryl trifluoromethyl ketones. *Tetrahedron Lett.* **2016**, *57*, 1220–1223. [[CrossRef](#)]
16. Wang, P.; Li, H.-F.; Zhao, J.-Z.; Du, Z.-H.; Da, C.-S. Organocatalytic Enantioselective Cross-Aldol Reaction of *o*-Hydroxyarylketones and Trifluoromethyl Ketones. *Org. Lett.* **2017**, *19*, 2634–2637. [[CrossRef](#)] [[PubMed](#)]
17. Wang, W.; Xiong, W.; Wang, J.; Wang, Q.-A.; Yang, W. Brønsted Acid-Catalyzed Asymmetric Friedel–Crafts Alkylation of Indoles with Benzothiazole-Bearing Trifluoromethyl Ketone Hydrates. *J. Org. Chem.* **2020**, *85*, 4398–4407. [[CrossRef](#)]
18. Carceller-Ferrer, L.; del Campo, A.G.; Vila, C.; Blay, G.; Muñoz, M.C.; Pedro, J.R. Catalytic Diastereo- and Enantioselective Synthesis of Tertiary Trifluoromethyl Carbinols through a Vinylogous Aldol Reaction of Alkylidenepyrazolones with Trifluoromethyl Ketones. *J. Org. Chem.* **2022**, *87*, 4538–4549. [[CrossRef](#)]
19. Blay, G.; Fernández, I.; Monleón, A.; Pedro, J.R.; Vila, C. Enantioselective Zirconium-Catalyzed Friedel–Crafts Alkylation of Pyrrole with Trifluoromethyl Ketones. *Org. Lett.* **2009**, *11*, 441–444. [[CrossRef](#)]
20. Kashikura, W.; Itoh, J.; Mori, K.; Akiyama, T. Enantioselective Friedel–Crafts Alkylation of Indoles, Pyrroles, and Furans with Trifluoropyruvate Catalyzed by Chiral Phosphoric Acid. *Chem. Asian J.* **2010**, *5*, 470–472. [[CrossRef](#)]
21. Le, T.P.; Higashita, K.; Tanaka, S.; Yoshimura, M.; Kitamura, M. Revisiting the Cu^{II}-Catalyzed Asymmetric Friedel–Crafts Reaction of Indole with Trifluoropyruvate. *Org. Lett.* **2018**, *20*, 7149–7153. [[CrossRef](#)] [[PubMed](#)]
22. Cai, L.; Zhao, Y.; Huang, T.; Meng, S.; Jia, X.; Chan, A.S.C.; Zhao, J. Chiral Phosphoric-Acid-Catalyzed Regioselective and Enantioselective C7-Friedel–Crafts Alkylation of 4-Aminoindoles with Trifluoromethyl Ketones. *Org. Lett.* **2019**, *21*, 3538–3542. [[CrossRef](#)] [[PubMed](#)]
23. Kasztelan, A.; Biedrzycki, M.; Kwiatkowski, P. High-Pressure-Mediated Asymmetric Organocatalytic Hydroxyalkylation of Indoles with Trifluoromethyl Ketones. *Adv. Synth. Catal.* **2016**, *358*, 2962–2969. [[CrossRef](#)]
24. Biedrzycki, M.; Kasztelan, A.; Kwiatkowski, P. High-Pressure Accelerated Enantioselective Addition of Indoles to Trifluoromethyl Ketones with a Low Loading of Chiral BINOL-Derived Phosphoric Acid. *ChemCatChem* **2017**, *9*, 2453–2456. [[CrossRef](#)]
25. Hua, Y.-Z.; Chen, J.-W.; Yang, H.; Wang, M.-C. Asymmetric Friedel–Crafts Alkylation of Indoles with Trifluoromethyl Pyruvate Catalyzed by a Dinuclear Zinc Catalyst. *J. Org. Chem.* **2018**, *83*, 1160–1166. [[CrossRef](#)]
26. Sasaki, S.; Yamauchi, T.; Higashiyama, K. Dy(OTf)₃/Pybox-catalyzed enantioselective Friedel–Crafts alkylation of indoles with α,β -unsaturated trifluoromethyl ketones. *Tetrahedron Lett.* **2010**, *51*, 2326–2328. [[CrossRef](#)]
27. Anokhin, M.V.; Feofanov, M.N.; Averin, A.D.; Beletskaya, I.P. The asymmetric Friedel–Crafts reaction of indoles with arylidene-malonates catalyzed by MgI₂/PyBox complexes. *ChemistrySelect* **2018**, *3*, 1388–1391. [[CrossRef](#)]
28. Young, C.M.; Taylor, J.E.; Smith, A.D. Evaluating aryl esters as bench-stable C(1)-ammonium enolate precursors in catalytic, enantioselective Michael addition–lactonisations. *Org. Biomol. Chem.* **2019**, *17*, 4747–4752. [[CrossRef](#)]

29. Zhao, H.-C.; Zhang, Z.-B.; Lu, W.-H.; Han, P.; Wang, W.; Jing, L.-H. 3-Carboxamide oxindoles as 1,3-C,N-bisnucleophiles for the highly diastereoselective synthesis of CF₃-containing spiro- δ -lactam oxindoles featuring acyl at the ortho-position of spiro carbon atom. *Tetrahedron Lett.* **2021**, *83*, 153426. [[CrossRef](#)]
30. Bao, J.-P.; Xu, C.-L.; Yang, G.-Y.; Wang, C.-X.; Zheng, X.; Yuan, X.-X. Novel 6a,12b-dihydro-6H,7H-chromeno [3,4-c] chromen-6-ones: Synthesis, structure and antifungal activity. *Molecules* **2019**, *24*, 1745. [[CrossRef](#)]
31. Yuan, X.; Wu, L.; Xu, C.; Pan, Z.; Shi, L.; Yang, G.; Wang, C.; Fan, S. A consecutive one-pot two-step approach to novel trifluoromethyl-substituted bis(indolyl)methane derivatives promoted by Sc(OTf)₃ and p-TSA. *Tetrahedron Lett.* **2019**, *60*, 151329. [[CrossRef](#)]
32. Shi, L.-J.; Liu, Y.; Wang, C.-X.; Yuan, X.-X.; Liu, X.; Wu, L.-L.; Pan, Z.-L.; Yu, Q.; Xu, C.-L.; Yang, G.-Y. Synthesis of 1-(beta-coumarinyl)-1-(beta-indolyl)trifluoroethanols through regioselective Friedel-Crafts alkylation of indoles with beta-(trifluoroacetyl)coumarins catalyzed by Sc(OTf)₃. *RSC Adv.* **2020**, *10*, 13929–13935. [[CrossRef](#)] [[PubMed](#)]
33. Yang, G.; Shi, L.; Pan, Z.; Wu, L.; Fan, L.; Wang, C.; Xu, C.; Liang, J. The synthesis of coumarin thiazoles containing a trifluoromethyl group and their antifungal activities. *Arab. J. Chem.* **2021**, *14*, 102880. [[CrossRef](#)]
34. Wu, L.; Yuan, X.; Yang, G.; Xu, C.; Pan, Z.; Shi, L.; Wang, C.; Fan, L. An eco-friendly procedure for the synthesis of new phosphates using KF/Al₂O₃ under solventless conditions and their antifungal properties. *J. Saudi Chem. Soc.* **2021**, *25*, 101273. [[CrossRef](#)]
35. Wang, X.; Bastow, K.F.; Sun, C.-M.; Lin, Y.-L.; Yu, H.-J.; Don, M.-J.; Wu, T.-S.; Nakamura, S.; Lee, K.-H. Antitumor Agents. Part 239. Isolation, Structure Elucidation, Total Synthesis, and anti-Breast Cancer Activity of Neo-tanshinlactone from *Salvia miltiorrhiza*. *J. Med. Chem.* **2004**, *47*, 5816–5819. [[CrossRef](#)]
36. Olmedo, D.; Sancho, R.; Bedoya, L.M.; López-Pérez, J.L.; DEL Olmo, L.M.B.; Muñoz, E.; Alcamí, J.; Gupta, M.P.; Feliciano, A.S. 3-Phenylcoumarins as Inhibitors of HIV-1 Replication. *Molecules* **2012**, *17*, 9245–9257. [[CrossRef](#)]
37. Matos, M.J.; Vazquez-Rodriguez, S.; Santana, L.; Uriarte, E.; Fuentes-Edfuf, C.; Santos, Y.; Muñoz-Crego, A. Synthesis and structure-activity relationships of novel amino/nitro substituted 3-arylcoumarins as antibacterial agents. *Molecules* **2013**, *18*, 1394–1404. [[CrossRef](#)]
38. Ahmad, I.; Thakur, J.P.; Chanda, D.; Saikia, D.; Khan, F.; Dixit, S.; Kumar, A.; Konwar, R.; Negi, A.S.; Gupta, A. Syntheses of lipophilic chalcones and their conformationally restricted analogues as antitubercular agents. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 1322–1325. [[CrossRef](#)]
39. Hanke, S.; Tindall, C.A.; Pippel, J.; Ulbricht, D.; Pirotte, B.; Ravaux, M.R.; Heiker, J.T.; Sträter, N. Structural Studies on the Inhibitory Binding Mode of Aromatic Coumarinic Esters to Human Kallikrein-Related Peptidase 7. *J. Med. Chem.* **2020**, *63*, 5723–5733. [[CrossRef](#)]
40. Wei, L.; Hou, T.; Li, J.; Zhang, X.; Zhou, H.; Wang, Z.; Cheng, J.; Xiang, K.; Wang, J.; Zhao, Y.; et al. Structure–Activity Relationship Studies of Coumarin-like Diacid Derivatives as Human G Protein-Coupled Receptor-35 (hGPR35) Agonists and a Consequent New Design Principle. *J. Med. Chem.* **2021**, *64*, 2634–2647. [[CrossRef](#)]
41. Yan, N.L.; Santos-Martins, D.; Nair, R.; Chu, A.; Wilson, I.A.; Johnson, K.A.; Forli, S.; Morgan, G.J.; Petrassi, H.M.; Kelly, J.W. Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. *J. Med. Chem.* **2021**, *64*, 6273–6299. [[CrossRef](#)] [[PubMed](#)]
42. Tao, M.; Wang, A.; Guo, P.; Li, W.; Zhao, L.; Tong, J.; Wang, H.; Yu, Y.; He, C. Visible-Light-Induced Regioselective Deaminative Alkylation of Coumarins via Photoredox Catalysis. *Adv. Synth. Catal.* **2021**, *364*, 24–29. [[CrossRef](#)]
43. Zhang, J.; Han, Q.; Jiang, Z.; Li, H.; Deng, M.; Zhu, K.; Li, M.; Duan, H. Chitinase inhibitors and synthesis and agricultural bioactivity of thiazolidinones: A review. *Chin. J. Pest. Sci.* **2021**, *23*, 421–437.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.